Results of the STIM1 and STIM2 Studies of Imatinib Cessation for Patients in Deep Molecular Response


Results of the STIM1 and STIM2 Studies of Imatinib Cessation for Patients in Deep Molecular Response
Slides from presentations at ASH 2013 and transcribed comments from a recent interview with Hagop M Kantarjian, MD (1/29/14)
Mahon FX et al. Long term follow-up after imatinib cessation for patients in deep molecular response: The update results of the STIM1 study. Proc ASH 2013;Abstract 255.

Mahon FX et al. Preliminary report of the STIM2 study: A multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Proc ASH 2013;Abstract 654.

Dr Kantarjian is Chairman and Professor in the Leukemia Department at The University of Texas MD Anderson Cancer Center in Houston, Texas.